Approximately 80% of alveolar rhabdomyosarcomas (ARMS) are characterized by the presence of either PAX3‐FOXO1 or PAX7‐FOXO1 fusion proteins and are thus termed fusion‐positive; embryonal rhabdomyosarcomas (ERMS) lack these fusions and are termed fusion‐negative [1, 2]. This evidence concerns the gene FOXO1 and embryonal rhabdomyosarcoma.